top of page
News, Events and Updates
Search
Anavex to Announce Fiscal 2023 Third Quarter Financial Results on Tuesday August 8, 2023
Aug 1, 2023
Long-term Clinical Study Demonstrates Disease-Modifying Effects of ANAVEX®2-73 for Rett Syndrome
Jun 28, 2023
Anavex Life Sciences and Partex Group Announce Strategic Partnership
Jun 27, 2023
Anavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
Jun 20, 2023
ANAVEX®2-73 Receives Compassionate Use Authorization for Pediatric Patients with Rett Syndrome
Jun 15, 2023
Anavex Life Sciences Reports Publication in Medical Journal for Continued Commitment to Improve RSBQ
Jun 12, 2023
Completion of ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial
Jun 6, 2023
ANAVEX Announces New U.S. Intellectual Property Compositions Patent for ANAVEX®2-73 (blarcamesine)
Jun 1, 2023
Anavex Life Sciences Reports Fiscal 2023 Second Quarter Financial Results
May 9, 2023
5
6
7
8
9
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
